<DOC>
	<DOC>NCT02566655</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of intravenous infusion of fucosylated autologous bone marrow cells as a new therapy in patients with established osteoporosis by a prospective, single-center, open, non-randomized and unblinded clinical trial.</brief_summary>
	<brief_title>Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Spinal Fractures</mesh_term>
	<criteria>Patients with established osteoporosis according to standard clinical criteria. Patients who give their written informed consent to participate in the study consent. Meet all the inclusion criteria Patients with concomitant systemic disease in the opinion of the investigator. Patients with rheumatoid arthritis, ankylosing spondylitis, chronic polyarticular arthritis. Current patients with neoplasm or history of any malignancy in the last 10 years except basal carcinoma or epidermoid skin. Patients with genetic disorders that are associated with secondary osteoporosis: Hemochromatosis, hypophosphatasia, osteogenesis imperfecta, EhlersDanlos syndrome, Marfan syndrome, Riley Day, porphyria, storage diseases syndrome. Patients receiving immunosuppressive chemotherapy or that could interfere with the process of cell proliferation. Transplant patients: bone marrow, kidney, liver, heart, lung. Patients with clinical criteria and anesthetics that contraindicate well sedation or bone marrow extraction. Patients participating in a clinical trial in the last 6 months. Patients with positive serology for hepatitis B, hepatitis C or HIV. Patients with inability to understand informed consent. Patients who are pregnant or breastfeeding actively. Patients physically fertile, defined as all women physiologically capable of becoming pregnant, UNLESS they are using reliable methods of contraception.</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>